Update on Helicobacter pylori infection study and key points of «Maastricht-V» consensus conference (2016)
https://doi.org/10.22416/1382-4376-2017-27-1-35-43
Abstract
Aim of review. To review in brief the reports of the XXIX international working meeting of the European Helicobacter pylori (H. pylori) and Microbiota Study Group (Magdeburg, 2016) and to discuss the key points of «Maastricht V» consensus meeting, devoted to diagnosis and treatment of infection. Key points. Association of H. pylori to both gastroenterological and non-gastrointestinal diseases and optimization of eradication therapy modes were discussed at the consensus conference. The special attention was paid for decreasing of infection burden and the stomach cancer prevention. New eradication therapy modes were presented for the regions with high and low H. pylori resistance to clarithromycin and metronidazole. It was demonstrated that clarithromycin resistance in Russia significantly varies in different regions and highest efficacy was observed for bismuth-based (in particular - bismuth tripotassium dicitrate) eradication modes. Conclusion. The guidelines of «Maastricht V» consensus meeting provide significant improvement of treatment results in H.pylori-infected patients as well as decrease of the risk of associated diseases (first of all - the stomach cancer).
About the Authors
A. A. Sheptulin
State educational state-funded institution of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
T. L. Lapina
State educational state-funded institution of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
V. O. Kaybysheva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
References
1. Müller A. Debate: H. pylori has protective potential. Pro. EHMSG XXIXth International Workshop. Magdeburg, 2016. - Oral presentation.
2. Labenz J. Debate: H. pylori has protective potential. Pro. EHMSG XXIXth International Workshop. Magdeburg, 2016. - Oral presentation.
3. Leja M., Rudule A., Park J. Y., et al. The preliminary results of GISTAR pilot study in Latvia. Helicobacter 2016; 21 (Suppl. 1):73.
4. Sjomina O., Pavlova J., Janovic P., et al. Is pepsinogen screening in general Caucasian population justified: results from a cross-sectional population study in Latvia. Helicobacter 2016; 21 (Suppl. 1):89.
5. Aine R., Kahar E., Aitokari K., et al. Atrophic gastritis (AG) and its clinical sequels among elderly people in Finland and Estonia. A comparative study using GastroPanel® and active B12-vitamin testing in four assisted-housing facilities. Helicobacter 2016; 21(Suppl. 1):95.
6. Schulz С., Selgrad M., H ringer М., et al. Time trends in Helicobacter pylori prevalence in HIV-infected subjects. Helicobacter 2016; 21 (Suppl. 1):105.
7. Molina-Infante J., Savarino E., Modolell I., et al. Association between Helicobacter pylori infection and eosinophilic esophagitis in a multicenter european prospective study. Helicobacter 2016; 21 (Suppl. 1):166.
8. Langner С., Link А., Tammer I. Comparison of microbiological and histological test for diagnosis of Helicobacter pylori infection. Helicobacter 2016; 21 (Suppl. 1):77.
9. Okuda М., Mabe К., Rikuchi S. Diagnostic accuracy of urine Helicobacter pylori antibody test in junior and senior high school students in Japan. Helicobacter 2016; 21 (Suppl. 1):78.
10. Bluemel B., Goelz H., Eisele B. Primary resistance of Helicobacter pylori to clarithromycin, levofloxacin and tetracycline in Germany. Helicobacter 2016 Sep; 21 (Suppl. 1):83.
11. Mеgraud F., Ducournau A.; Bеnеjat E., et al. Surveillance of Helicobacter pylori resistance to antibiotics in France in 2014. Helicobacter 2016; 21 (Suppl. 1):110.
12. Dekhnich N. N., Ivanchik N. V., Kozlov R. S., et al. Antimicrobial susceptibility of Helicobacter pylori isolates in Smolensk, Russia in 2015-2016. Helicobacter. 2016; 21 (Suppl. 1):125.
13. Graham D. Y., Lu H., Dore M. P. Empiric 4-drug nonbismuth Helicobacter pylori therapies promote misuse (overuse) of antibiotics. Helicobacter 2016; 21 (Suppl. 1):139.
14. McNichol A.G., Megraud F., Tepes B., et al. Paneuropean registry on Helicobacter pylori management (Hp-EuReg): interimanalysis of the rescue treatment with bismuth, levofloxacin and amoxicillin. Helicobacter 2016; 21 (Suppl. 1):150.
15. Cheung D.; Seong H., Kim J., Park S. The impact of the probiotics of Lactobacillus acidophilus on the outcomes of Helicobacter pylori eradication treatment. Helicobacter 2016; 21 (Suppl. 1):150.
16. Malferheiner P. Welcome and introduction. Satellite Symposium «What’s new in Helicobacter pylori eradication. The renaissance of bismuth». EHMSG XXIXth International Workshop. Magdeburg, 2016. Oral presentation.
17. Megraud F. Overcoming Helicobacter pylori antibiotic resistance in Europe with bismuth.c Satellite Symposium «What’s new in Helicobacter pylori eradication. The renaissance of bismuth». EHMSG XXIXth International Workshop. Magdeburg, 2016. - Oral presentation.
18. Bazzoli F. Update on management of Helicobacter pylori infection and the role of bismuth. Satellite Symposium «What’s new in Helicobacter pylori eradication. The renaissance of bismuth». EHMSG XXIXth International Workshop. Magdeburg, 2016. - Oral presentation.
19. Шептулин А. А., Визе-Хрипунова М.А. Современные возможности применения препаратов висмута в гастроэнтерологии. Рос журн гастроэнтерол гепатол колопроктол 2010; 20(3):63-7.
20. Malfertheiner P, Megraud F., O’Morain C.A., et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut 2016 October 5. doi: org/10.1136/gutjnl-2016-312288.
21. Talley N. J., Janssens L., Lauritsen K., et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 month follow up. Br Med J 1999; 318:833-7.
22. Осипенко М. Ф., Бикбулатова Е. А., Шакалите Ю. Д. и др. Резистентность Helicobacter pylori к кларитромицину в Новосибирске. Эксперим клин гастроэнтерол 2012; 8:15-7.
23. Дехнич Н. Н., Костякова Е. А., Пунин А. А. и др. Антибиотикорезистентность H. pylori: результаты микробиологического регионального исследования. Рос журн гастроэнтерол гепатол 2011; 21(2):37-42.
24. Нижевич А. А. Клинико-морфологическая характеристика, генетические маркеры, диагностика и лечение НР-ассоциированных заболеваний у детей. Автореф. дис. … канд. мед. наук. М., 2010.
25. Корниенко Е.А., Суворов А.Н., Ткаченко Е.И. и др. Критический рост резистентности Helicobacter pylоri к кларитромицину и педиатрической и взрослой гастроэнтерологической практике. Справочник поликлинического врача 2010; 12:54-6.
26. Gispert J. Maastricht V: Key messages in treatment. - EHMSG XXIXth International Workshop. Magdeburg, 2016. - Oral presentation.
27. Graham D. Y., LeeYi-Chia, Wu Mimg-Siang Rational Helicobacter pylori therapy: based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12:177-86.
Review
For citations:
Sheptulin A.A., Lapina T.L., Kaybysheva V.O. Update on Helicobacter pylori infection study and key points of «Maastricht-V» consensus conference (2016). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):35-43. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-1-35-43
Views:
2379
Email this article 
